2026-01-27 - Analysis Report
**Financial Report for Johnson & Johnson (JNJ)**

**Company Overview**
Johnson & Johnson is a multinational corporation dedicated to developing and delivering medical devices, pharmaceuticals, and consumer packaged goods.

**Return Rate Comparison**

- **Cumulative Return of Review Stock (JNJ)**: 78.20%
- **Cumulative Return of Comparison Stock (VOO, S&P 500)**: 127.58%
- **Divergence**: -49.30 (max: 13.50, min: -92.80, current: -49.30)
- **Relative Divergence**: 40.90%

The review stock (JNJ) has a lower cumulative return rate compared to the comparison stock (VOO, S&P 500). The current divergence of -49.30 indicates a significant gap between the return rates of the two stocks.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 9.0% | 16.9% | 0.0% | 0.7 | 310.9B |
| 2017-2019  | 21.0% | 16.9% | -4.0% | 0.7 | 351.4B |
| 2018-2020  | 13.0% | 25.9% | -11.0% | 0.7 | 379.2B |
| 2019-2021  | 26.0% | 25.9% | -38.0% | 0.6 | 412.2B |
| 2020-2022  | 15.0% | 25.9% | 11.0% | 0.5 | 425.6B |
| 2021-2023  | -11.0% | 14.1% | -29.0% | 0.3 | 377.6B |
| 2022-2024  | -23.0% | 14.1% | -52.0% | 0.2 | 348.4B |
| 2023-2025  | 37.0% | 14.1% | -38.0% | 0.1 | 498.6B |

The review stock's alpha indicates varying performance across different time periods, with values ranging from 0.0% to -38.0%. The beta values of 0.7-0.3 indicate low to moderate volatility in relation to the market.

**Recent Stock Price Fluctuations**

- **Close**: $221.49
- **5-day SMA**: $219.27
- **20-day SMA**: $211.98
- **60-day SMA**: $204.34

The 5-day and 20-day SMAs are above the close price, indicating short-term upward momentum. The 60-day SMA is below the close price, suggesting long-term upward momentum. However, the recent sharp rebound suggests a fluctuation issue.

**RSI, PPO Analysis**

- **Market Risk Indicator (MRI)**: 0.70
- **RSI**: 82.42
- **PPO**: 0.37

The MRI indicates a medium-risk investment. The RSI value of 82.42 suggests overbought conditions. The PPO suggests a downward trend. Hybrid Signal indicates a buy signal with a cash allocation of 0%.

**Recent News & Significant Events (Yahoo Finance)**

[2026-01-22] How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily
[2026-01-26] Johnson & Johnson Stock: 2026 Outlook After 50% Gains - TIKR.com
[2026-01-26] Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore
[2026-01-26] Johnson & Johnson stock is nudging higher — here’s what traders are watching this week - TechStock²
[2026-01-26] Johnson & Johnson a Top Ranked SAFE Dividend Stock With 2.4% Yield (JNJ) - Nasdaq
[2026-01-21] J&J sees 2026 profit above Wall Street estimates despite tariffs hit, Trump pricing deal - Reuters

Recent headlines suggest positive sentiment around the company's performance and prospects.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 224.09 / 265.00 / 155.00

Analysts' mean rating of 2.16 suggests a buy recommendation. Target prices range widely, indicating varying predictions for future stock performance.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----:|---:|-----:|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3 | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

EPS values range widely, indicating fluctuating performance across different quarters. Revenue values also vary, suggesting changes in the company's financial situation.

**Quarterly Financial Information**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |

Revenue and profit margin values vary across different quarters. Equity values also fluctuate, indicating changes in the company's capital structure. ROE values suggest varying profitability across different quarters.

**Comprehensive Analysis**

Overall, the review stock (JNJ) has a lower cumulative return rate compared to the comparison stock (VOO, S&P 500). The analysis of the review stock's alpha and beta values suggests varying performance across different time periods and low to moderate volatility in relation to the market. Recent stock price fluctuations indicate short-term upward momentum but a long-term upward trend. Analysis of RSI and PPO indicators suggests overbought conditions and a downward trend, respectively. The MRI indicates a medium-risk investment. Recent headlines suggest positive sentiment around the company's performance and prospects. Analyst consensus suggests a buy recommendation with varying predictions for future stock performance. Quarterly earnings and financial information indicate fluctuating performance across different quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.